XML Financial LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

XML Financial LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,284 shares of the biopharmaceutical company’s stock after purchasing an additional 52 shares during the quarter. XML Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $885,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TrueWealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $207,000. Walker Asset Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $436,000. Ascent Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 55.1% during the 2nd quarter. Ascent Group LLC now owns 940 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 334 shares during the period. Wipfli Financial Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $555,000. Finally, US Bancorp DE grew its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. US Bancorp DE now owns 5,783 shares of the biopharmaceutical company’s stock worth $3,984,000 after purchasing an additional 74 shares during the period. 84.25% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $790.00 to $856.00 in a research note on Wednesday, November 9th. The Goldman Sachs Group raised their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $970.00 and gave the stock a “buy” rating in a research note on Monday, October 3rd. JPMorgan Chase & Co. raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 price objective on the stock in a research note on Friday, January 20th. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, StockNews.com assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $786.15.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director N Anthony Coles sold 5,758 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $714.11, for a total transaction of $4,111,845.38. Following the transaction, the director now owns 1,093 shares in the company, valued at approximately $780,522.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director N Anthony Coles sold 5,758 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $714.11, for a total transaction of $4,111,845.38. Following the transaction, the director now owns 1,093 shares in the company, valued at approximately $780,522.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 4th. The stock was sold at an average price of $727.82, for a total value of $727,820.00. Following the transaction, the executive vice president now owns 19,644 shares in the company, valued at approximately $14,297,296.08. The disclosure for this sale can be found here. Insiders have sold a total of 19,212 shares of company stock worth $14,070,511 in the last quarter. Company insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3 %

Shares of REGN opened at $727.47 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $779.00. The company has a quick ratio of 4.52, a current ratio of 5.36 and a debt-to-equity ratio of 0.13. The firm’s fifty day moving average is $732.22 and its two-hundred day moving average is $690.27. The stock has a market cap of $79.22 billion, a PE ratio of 15.34, a price-to-earnings-growth ratio of 2.17 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported $9.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.55 by $1.43. Regeneron Pharmaceuticals had a net margin of 39.17% and a return on equity of 31.16%. The company had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.79 billion. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.45 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.